My Medical Blog http://mymedblog.com/ ru My Medical Blog DataLife Engine XANAX: HOW SUPPLIED http://mymedblog.com/xanax/31-xanax-how-supplied.html http://mymedblog.com/xanax/31-xanax-how-supplied.html XANAX: HOW SUPPLIED

XANAX Tablets are available as follows:
 

0.25 mg (white, oval, scored, imprinted “XANAX 0.25”)
Bottles of 100 NDC 0009-0029-01
Reverse Numbered
Unit dose (100) NDC 0009-0029-46
Bottles of 500 NDC 0009-0029-02
Bottles of 1000 NDC 0009-0029-14]]> support Mon, 06 Oct 2008 01:02:15 +0400 XANAX: Drug Interactions http://mymedblog.com/xanax/30-xanax-drug-interactions.html http://mymedblog.com/xanax/30-xanax-drug-interactions.html XANAX: Drug Interactions

Use with Other CNS Depressants

If XANAX Tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines.

The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol and other drugs which themselves produce CNS depression.

Use with Imipramine and Desipramine
The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of XANAX Tablets in doses up to 4 mg/day. The clinical significance of these changes is unknown.]]> support Mon, 06 Oct 2008 00:47:51 +0400 XANAX: PRECAUTIONS http://mymedblog.com/xanax/29-xanax-precautions.html http://mymedblog.com/xanax/29-xanax-precautions.html XANAX: PRECAUTIONS

As with other psychotropic medications, the usual precautions with respect to administration of the drug and size of the prescription are indicated for severely depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans. Panic disorder has been associated with primary and secondary major depressive disorders and increased reports of suicide among untreated patients.
Mania
Episodes of hypomania and mania have been reported in association with the use of XANAX in patients with depression.
Uricosuric Effect
Alprazolam has a weak uricosuric effect. Although other medications with weak uricosuric effect have been reported to cause acute renal failure, there have been no reported instances of acute renal failure attributable to therapy with XANAX.
Use in Patients with Concomitant Illness
It is recommended that the dosage be limited to the smallest effective dose to preclude the development of ataxia or oversedation which may be a particular problem in elderly or debilitated patients. The usual precautions in treating patients with impaired renal, hepatic or pulmonary function should be observed. There have been rare reports of death in patients with severe pulmonary disease shortly after the initiation of treatment with XANAX. A decreased systemic alprazolam elimination rate (eg, increased plasma half-life) has been observed in both alcoholic liver disease patients and obese patients receiving XANAX.]]> support Mon, 06 Oct 2008 00:36:45 +0400 XANAX: INDICATIONS AND USAGE http://mymedblog.com/xanax/28-xanax-indications-and-usage.html http://mymedblog.com/xanax/28-xanax-indications-and-usage.html XANAX: INDICATIONS AND USAGE

Anxiety Disorders

XANAX Tablets (alprazolam) are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-IIIR] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety.

Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of 6 months or longer, during which the person has been bothered more days than not by these concerns. ]]> support Mon, 06 Oct 2008 00:18:41 +0400 XANAX: clinical studies http://mymedblog.com/xanax/27-xanax-clinical-studies.html http://mymedblog.com/xanax/27-xanax-clinical-studies.html Xanax: CLINICAL STUDIES

Anxiety Disorders
XANAX Tablets were compared to placebo in double blind clinical studies (doses up to 4 mg/day) in patients with a diagnosis of anxiety or anxiety with associated depressive symptomatology. XANAX was significantly better than placebo at each of the evaluation periods of these 4-week studies as judged by the following psychometric instruments: Physician’s Global Impressions, Hamilton Anxiety Rating Scale, Target Symptoms, Patient’s Global Impressions and Self-Rating Symptom Scale.

Panic Disorder
Support for the effectiveness of XANAX in the treatment of panic disorder came from three short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.
The average dose of XANAX was 5-6 mg/day in two of the studies, and the doses of XANAX were fixed at 2 and 6 mg/day in the third study. In all three studies, XANAX was superior to placebo on a variable defined as "the number of patients with zero panic attacks" (range, 37- 83% met this criterion), as well as on a global improvement score. In two of the three studies, XANAX was superior to placebo on a variable defined as "change from baseline on the number of panic attacks per week" (range, 3.3-5.2), and also on a phobia rating scale. A subgroup of patients who were improved on XANAX during short-term treatment in one of these trials was continued on an open basis up to 8 months, without apparent loss of benefit.

]]> support Sun, 05 Oct 2008 23:39:27 +0400 XANAX: DESCRIPTION http://mymedblog.com/xanax/26-xanax-description.html http://mymedblog.com/xanax/26-xanax-description.html XANAX®

alprazolam tablets, USP


DESCRIPTION

XANAX Tablets contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.

The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-α] [1,4] benzodiazepine.

The structural formula is represented to the right:

 

Alprazolam is a white crystalline powder, which is soluble in methanol or ethanol but which has no appreciable solubility in water at physiological pH. Each XANAX Tablet, for oral administration, contains 0.25, 0.5, 1 or 2 mg of alprazolam.

XANAX Tablets, 2 mg, are multi-scored and may be divided as shown below:


 

Inactive ingredients: Cellulose, corn starch, docusate sodium, lactose, magnesium stearate, silicon dioxide and sodium benzoate. In addition, the 0.5 mg tablet contains FD&C Yellow No. 6 and the 1 mg tablet contains FD&C Blue No. 2.

]]> support Mon, 25 Aug 2008 23:42:32 +0400